Choreo LLC Invests $776,000 in Genmab A/S (NASDAQ:GMAB)

Choreo LLC purchased a new position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 31,200 shares of the company's stock, valued at approximately $776,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GMAB. DDD Partners LLC bought a new stake in Genmab A/S during the second quarter worth $8,860,000. Capital International Investors increased its holdings in shares of Genmab A/S by 7.8% in the first quarter. Capital International Investors now owns 4,373,277 shares of the company's stock valued at $130,805,000 after purchasing an additional 315,355 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of Genmab A/S by 16.0% in the fourth quarter. First Trust Advisors LP now owns 1,270,095 shares of the company's stock valued at $40,440,000 after purchasing an additional 175,292 shares during the last quarter. Trexquant Investment LP acquired a new position in shares of Genmab A/S in the fourth quarter valued at $4,875,000. Finally, Harding Loevner LP increased its holdings in shares of Genmab A/S by 2.7% in the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company's stock valued at $97,569,000 after purchasing an additional 85,665 shares during the last quarter. 7.07% of the stock is owned by institutional investors.

Genmab A/S Trading Up 1.5 %

NASDAQ:GMAB traded up $0.41 on Friday, reaching $26.90. 506,451 shares of the stock traded hands, compared to its average volume of 572,483. The firm has a market capitalization of $17.79 billion, a price-to-earnings ratio of 22.42, a price-to-earnings-growth ratio of 0.81 and a beta of 0.99. The company's 50 day moving average is $27.25 and its 200-day moving average is $28.07. Genmab A/S has a 1-year low of $24.53 and a 1-year high of $38.80.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The company had revenue of $779.50 million for the quarter, compared to analyst estimates of $734.60 million. On average, equities research analysts forecast that Genmab A/S will post 1.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on GMAB. Royal Bank of Canada upgraded shares of Genmab A/S from a "sector perform" rating to an "outperform" rating in a report on Monday, July 15th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Friday. BTIG Research upped their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a "buy" rating in a research report on Thursday, June 27th. Morgan Stanley reissued an "equal weight" rating and issued a $31.00 target price on shares of Genmab A/S in a report on Wednesday. Finally, Truist Financial dropped their target price on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a report on Monday, September 9th. Two analysts have rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.